22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
21:30 , Nov 18, 2016 |  BC Week In Review  |  Financial News

BeyondSpring proposes IPO

BeyondSpring proposed to raise up to $100 million in an IPO on NASDAQ underwritten by Citigroup, Guggenheim Securities, FBR, China Renaissance and Trout Capital. BeyondSpring Pharmaceuticals Inc. , New York, N.Y. ...
22:33 , Nov 15, 2016 |  BC Extra  |  Financial News

BeyondSpring aiming for $100M IPO

BeyondSpring Pharmaceuticals Inc. (New York, N.Y.) proposed to raise up to $100 million in an IPO on NASDAQ underwritten by Citigroup, Guggenheim Securities, FBR, China Renaissance and Trout Capital. The company plans to advance plinabulin...
07:00 , Oct 10, 2016 |  BC Week In Review  |  Clinical News

Plinabulin: Phase Ib/II started

BeyondSpring said investigators began an open-label, U.S. Phase Ib/II trial to evaluate 3.5, 20, 30 and 40 mg IV plinabulin on days 1, 8 and 15 plus IV Opdivo nivolumab on days 1 and 15...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Plinabulin: Phase I started

BeyondSpring said an investigator began an open-label, U.S. Phase I trial to evaluate 3.5, 20, 30 and 40 mg/m 2 IV plinabulin on days 1, 8 and 15 plus IV Opdivo nivolumab on days 1...
08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Fred Hutchinson, BeyondSpring Pharmaceuticals deal

Fred Hutchinson will grant BeyondSpring options to license development rights to up to six new cancer treatment or diagnostic projects per year for five years. Both companies will conduct preclinical and clinical development on optioned...
01:32 , Jan 7, 2016 |  BC Extra  |  Company News

BeyondSpring gains options for Fred Hutch programs

BeyondSpring Pharmaceuticals Inc. (New York, N.Y.) began a five-year partnership with Fred Hutchinson Cancer Research Center (Seattle, Wash.) to develop cancer treatments and diagnostics. The hybrid U.S.-China co-development company will have the option to license...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

Plinabulin: Phase II data

An open-label, international Phase II trial in 105 patients with advanced NSCLC showed that 30 mg/m 2 plinabulin plus docetaxel missed the primary endpoint of improving median OS vs. docetaxel alone (8.7 vs. 7.5 months,...